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1ABSTRACT
Does the pattern of striatal dopamine depletion 
contribute to non-motor symptoms in Parkinson’s disease?
Su Jin Chung
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Young H. Sohn)
Background : Non-motor symptoms (NMS) has been recognized as a key 
determinant factor for quality of life in Parkinson’s disease (PD), but the 
mechanism underlying NMS in PD has not yet been elucidated well. To 
investigate whether the pattern of striatal dopamine depletion contributes to
NMS in PD, we hypothesized that PD patients with greater NMS might have a 
different pattern of striatal dopamine depletion, particularly the areas other than 
the posterior putamen, compared to those with less NMS.
Methods : We conducted a survey of the degree of NMS (using non-motor 
symptoms scale, NMSS) in 151 PD patients who had been initially diagnosed at 
our hospital by dopamine transporter (DAT) scanning, using a [18F] 
N-(3-Fluoropropyl)-2β-carbon ethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) 
PET scan (from March 2009 to June 2013).
Results : Patients with a high NMSS score (above the median) had an older age 
of PD onset (64.9 ± 9.1 vs 61.5 ± 10.1 years, p = 0.034), a higher initial part III 
2of the Unified Parkinson Disease rating scale (UPDRS-motor, assessed in 
drug-naïve state) (26.9 ± 11.7 vs 20.9 ± 10.3, p = 0.003), a higher levodopa-
equivalent dose (636.3 ± 293.0 vs 524.4 ± 196.2, p = 0.007), and a greater Beck 
Depression Inventory (BDI) score (14.7 ± 8.1 vs 11.5 ± 7.5, p = 0.013), 
compared to those with a low NMSS score. A general linear model showed that 
patients with a high NMSS score had significantly higher UPDRS-motor score 
than those with a low score after controlling for onset age, gender, symptom 
duration, BDI score, and DAT activity in the posterior putamen (p = 0.034). 
However, DAT activities in 6 striatal subregions and inter-subregional ratios 
(ISRs) were comparable between the two groups. There were no correlations
between subregional DAT activities and NMSS scores (either total or each 
domain scores), except for the mood/cognition domain score, which was 
negatively correlated to the anterior putamen/posterior putamen ISR (r = -0.175, 
p = 0.032).
Conclusion : This study demonstrates that the pattern of striatal dopamine 
depletion does not contribute to the degree of NMS in early PD, although some 
clinical features are different between the patients with greater NMS and those 
with less NMS. This study also suggests that patients with less NMS may have 
a benign course of motor symptom progression, compared to those with more 
NMS. NMS in PD may be more likely associated with extra-striatal lesions 
accompanied in PD than striatal dopaminergic deficits.
----------------------------------------------------------------------------------------
Key words : non-motor symptoms; parkinson’s disease; striatal dopamine 
depletion
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I. INTRODUCTION
Parkinson’s disease (PD) is a chronic degenerative disorder of the central 
nervous system, resulting in motor disability such as bradykinesia, rigidity, 
resting tremor, and postural instability. Besides motor symptoms, PD is also 
accompanied by variety of non-motor symptoms (NMS) involving sleep, mood, 
cognition, attention, and autonomic functions. NMS can occur across all stage 
of PD, and has been recognized as a key determinant factor for quality of life in 
PD patients. Some NMS such as olfactory deficit, constipation, rapid eye 
movement sleep behavior disorder (RBD), and depression may precede the 
motor symptoms by many years.1 In contrast to the motor symptoms, NMS may 
be easily misdiagnosed, and may have inappropriate medical interventions.2
Although the importance of NMS in PD has been widely recognized in recent 
years, the mechanism underlying NMS has not yet been elucidated well.
The motor symptoms of PD result mainly from the loss of dopaminergic 
4neurons in the substantia nigra, but PD pathology also involves widespread 
brainstem and cortical lesions with alterations of several neurotransmitters other 
than dopamine, such as serotonin, norepinephrine, and acetylcholine.3 Similar to 
motor symptom fluctuation, the presence of NMS fluctuation in advanced PD 
patients has been well recognized. Some NMSs are exacerbated during the 
off-period, suggesting a potential dopaminergic contribution. The importance of 
the dopaminergic contribution to NMS in PD was highlighted by a recent 
positron emission tomography (PET) study, in which dopaminergic depletion in 
the hypothalamus is associated with the development of sleep, endocrine, and 
autonomic dysfunctions.4 A number of clinical trials have demonstrated a 
beneficial effect of speciﬁc dopaminergic drugs on some NMSs, such as RBD, 
pain, restless leg syndrome, and depression.5 However, a majority of NMSs may 
seldom respond to PD medications, and some of them can even be exacerbated 
by dopaminergic treatments. Thus, the pathophysiological mechanism 
underlying NMS in PD is still unclear, and appears to be more heterogeneous 
than pure dopaminergic deficits.6
Dopamine transporter (DAT) activity, since it represents the integrity of 
presynaptic dopaminergic neurons in the striatum, has been widely used as an 
imaging biomarker for the diagnosis of PD. Accordingly, various techniques 
using different radioligands have been developed for this purpose, and used in 
clinical practice. Among them, [18F] N-(3-Fluoropropyl)-2β-carbon 
ethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) PET has been available in 
Korea as well as in our hospital since 2008.7 Compared to DAT single photon 
emission computed tomography (SPECT), 18F-FP-CIT PET has better spatial 
5resolution and more sophisticated attenuation correction, and can be used to 
evaluate subregional changes in the striatal DAT.8 Compared to healthy people, 
DAT activity is significantly reduced in all areas of the striatum in PD patients, 
but the degree of reduction is different among the striatal subregions. In PD 
patients, DAT reduction in the posterior putamen is much greater than that in 
other striatal subregions.9,10 In addition, inter-subregional ratios (ISRs) are also 
different among various parkinsonism, suggesting the diverse patterns of striatal 
dopaminergic depletion specific to different parkinsonism syndromes.10
Therefore, we performed this study to investigate whether the pattern of 
striatal dopamine depletion contributes to NMS accompanied in PD. We 
hypothesized that PD patients with greater NMS might have a different pattern 
of striatal dopamine depletion, particularly the striatal subregions other than the 
posterior putamen, compared to those with less NMS. Secondly, in this study, 
we also investigated whether early PD patients with greater NMS have different 
clinical features compared to those with less NMS.
II. MATERIALS AND METHODS
1. Subjects
We conducted a survey of the degree of NMS (using Korean version of the 
non-motor symptoms scale, NMSS) in PD patients who had been initially 
diagnosed at our hospital by DAT scanning, using a 18F-FP-CIT PET scan (from 
March 2009 to June 2013). PD in these patients was diagnosed according to the 
clinical criteria of the UK PD Brain Bank,8 the presence of appropriate DAT 
defects on 18F-FP-CIT PET scans,10 and the presence of PD drug response 
6during follow-up (≥ 18 months). The interpretation of 18F-FP-CIT-PET scans 
was performed by nuclear medicine physicians who were blind to the clinical 
status of each patient. For this study, we excluded the patients with having focal 
lesions or lacunar infarctions in the basal ganglia, those with atypical 
parkinsonism or secondary parkinsonism, those having severe medial illness 
which could affect NMS, and those were taking dopaminergic medication in 
other hospital already. The part III of the Unified Parkinson Disease rating scale 
(UPDRS-motor) and modified Hoehn and Yahr stage (HYS) were used to assess 
PD motor severity at the time of the diagnosis. Mini-mental State Examination 
(MMSE), Beck Depression Inventory (BDI), and Cross Cultural Smell 
Identification Test (CCSIT)11 were performed as a routine diagnostic work-up. 
Parkinsonian medications prescribed at the time of NMSS assessment were 
checked, and levodopa-equivalent dose (LED) was calculated on the basis of 
previously described methodology.12 We received approval from the Ethics 
committee of our hospital for experiments using human participants.
2. Assessment of non-motor symptoms
The original NMSS was developed for NMS assessment in PD patients by 
the International Parkinson’s Disease Non-Motor Group,13 and has been widely 
used in clinical studies of PD. The Korean version of the NMSS has been 
developed and validated.14 The NMSS is composed of thirty items that are
grouped to the nine domains: cardiovascular including falls (2 items),
sleep/fatigue (4 items), mood/cognition (6 items), perceptual 
problems/hallucinations (3 items), attention/memory (3 items), gastrointestinal 
7tract (3 items), urinary (3 items), sexual function (2 items), and miscellaneous 
(4 items; pain, taste or smell, weight change, and excessive sweating). Score for 
each item is based on a multiple of severity (from 0 to 3) and frequency scores 
(from 1 to 4). The total NMSS score ranged from 0 to 360, in which higher 
score represents more severe NMS. The NMSS was rated by a neurologist, and 
obtained through interviews of the patients and their caregivers.
3. PET-CT image acquisition 
18F-FP-CIT PET scans were used with a GE Discovery STe (DSTE) PET-CT 
scanner (GE Healthcare Technologies, Milwaukee, WI). DAT images were 
obtained with 3D resolution, and performed a post hoc 3D Gaussian smoothing 
with 2.3 mm full width at half maximum. After fasting for at least 6 hours 
before PET scanning, 5 mCi (185 MBq) of 18F-FP-CIT was injected 
intravenously. Images were taken in a 3D mode at 120 KVp and 380 mAs 
during a 20- minute session that came about 90 minutes after injection.
4. Quantitative analysis of 18F-FP-CIT PET data 
Quantitative analyses of 18F-FP-CIT PET data were fulfilled through a 
previously described procedure.10 Image processing was performed using SPM8 
(Wellcome Department of Imaging Neuroscience, Institute of Neurology, UCL, 
London, UK) under MATLAB 2013a for Windows (MathWorks, Natick, MA). 
Quantitative analyses were based on volumes of interests (VOIs), which were 
defined based on a template in standard space. All reconstructed PET images 
were spatially normalized to Montreal Neurology Institute (MNI) template 
8space using a standard 18F-FP-CIT PET template, which was made using 
18F-FP-CIT PET and T1 MRI of 13 normal controls to remove inter-subject 
anatomical variability. Twelve VOIs of bilateral striatal subregions and one 
occipital VOI were drawn on a co-registered spatially normalized single T1 
MRI and 18F-FP-CIT PET template image on MRIcro version 1.37 (Chris 
Rorden, Columbia, SC), based on previous study (Figure 1).10 These VOIs were 
adjusted by a minor translation in our in-house VOI editing software called 
ANTIQUE.15 Using DAT activity concentration in each VOI, we estimated the 
surrogate of nondisplaceable binding potential (BPND), defined as follows: 
(mean standardized uptake value [SUV] of the striatal subregions VOI - mean 
SUV of the occipital VOI)/mean SUV of the occipital VOI.16 We used mean 
BPND for each bilateral striatal subregions. The ISR was defined as the ratio of 
DAT activity of one striatal subregion to that of another striatal subregion. 
Posterior putamen was used to the common denominator, and 5 ISRs were 
calculated.
9Figure 1. Images of 18F-FP-CIT uptakes at the level of striatum. A healthy 
control (A), and diagram of 6 striatal subregions (B).
VS: ventral striatum, AC: anterior caudate, PC: posterior caudate, AP: anterior 
putamen, PP: posterior putamen, VP: ventral putamen.
A
B
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5. Statistical analysis
Data were expressed as means ± SDs. We divided the patients into two 
groups according to their total NMSS scores (above the median and the median
or less). An independent t test was used to compare numeric variables, and χ2 
test was used to compare categorical variables between the patients with greater 
NMS and those with less NMS. A general linear model was used to compare the 
difference of UPDRS-motor score between the two groups after controlling for 
onset age, gender, duration of motor symptoms, BDI score, and DAT activity in 
the posterior putamen. A partial correlation analysis was conducted to evaluate 
the relationship between striatal subregional DAT activity and the NMSS scores 
(total and each domain scores), after controlling for the follow-up duration
(intervals from DAT scan to the NMSS). SPSS Statistics 20 (IBM SPSS, 
Armonk, NY, USA) was used to perform all statistical analyses. P–values <0.05
were regarded as significant.
III. RESULTS
One hundred and fifty-one patients (mean age, 67.9 ± 9.6 years; range, 41 –
88 years; 67 men) were included in this study. Total NMSS score in each patient
ranged from 0 to 169 (mean, 45.5 ± 34.0; median, 37). Seventy-six (50.3%) 
patients belonged to the low NMSS group (total NMSS ≤ 37), while 
seventy-five (49.7%) patients were in the high NMSS group (total NMSS > 37). 
Clinical characteristics of the two patient groups are shown in Table 1. High 
NMSS patients were older PD onset age (64.9 ± 9.1 vs 61.5 ± 10.1 years, p = 
0.034), had a higher initial UPDRS-motor score (26.9 ± 11.7 vs 20.9 ± 10.3, p = 
11
0.003), more severe initial HYS (p = 0.017), a higher LED at follow-up (636 ± 
293 vs 524 ± 196, p = 0.007), and a higher BDI score (14.7 ± 8.1 vs 11.5 ± 7.5, 
p = 0.013), compared to low NMSS patients. A general linear model showed 
that high NMSS patients had significantly higher UPDRS-motor score than low 
NMSS patients after controlling for onset age, gender, duration of motor 
symptoms, BDI score, and DAT activity in the posterior putamen (p = 0.034) 
(Figure 2). However, DAT activities in 6 striatal subregions and ISRs were 
comparable between the two groups (Table 2).
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Table 1. Clinical characteristics of the two patient groups
Data are means ± SDs. 
UPDRS: Unified Parkinson’s Disease rating scale, MMSE: Mini-Mental State 
Examination, BDI: Beck Depression Inventory, CCSIT: Cross Cultural Smell 
Identification Test.
Low
NMSS score 
(n=76)
High
NMSS score 
(n=75)
p-value
Onset age (years) 61.5 ± 10.1 64.9 ± 9.1 0.034
Gender (% man) 44.7 44.0 0.927
Education (years) 10.0 ± 4.7 8.9 ± 5.9 0.248
Duration of motor symptoms (years) 1.2 ± 0.9 1.5 ± 1.3 0.058
Follow-up duration (years) 3.3 ± 1.2 3.5 ± 1.3 0.297
Initial UPDRS-motor score 20.9 ± 10.3 26.9 ± 11.7 0.003
Initial Hoehn and Yahr stage (%) 0.017
1.0/1.5 34.8 20.0
2.0/2.5 62.1 64.6
3.0/4.0 3.0 15.4
Levodopa-equivalent dose (mg) 524.4 ± 196.2 636.3 ± 293 0.007
MMSE score 25.9 ± 2.9 25.6 ± 3.6 0.631
BDI score 11.5 ± 7.5 14.7 ± 8.1 0.013
CCSIT score 6.9 ± 2.5 6.9 ± 2.6 0.847
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Figure 2. A scatterplot showing the relationship between DAT activity in the 
posterior putamen and UPDRS-motor score in each patient. Low NMSS score 
patients (circle) represent significantly lower UPDRS-motor score at same DAT 
activity in the posterior putamen than high NMSS score patients (rectangle).
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Table 2. 18F-FP-CIT uptakes of striatal subregions and inter-subregional ratios 
between the two patient groups
Low
NMSS score 
(n=76)
High
NMSS score 
(n=75)
p-value
Striatal subregions
VS 2.38 ± 0.57 2.32 ± 0.66 0.578
AC 2.09 ± 0.67 2.11 ± 0.83 0.873
PC 1.30 ± 0.47 1.32 ± 0.56 0.811
AP 2.13 ± 0.60 2.06 ± 0.68 0.510
PP 1.21 ± 0.39 1.19 ± 0.44 0.690
VP 1.40 ± 0.37 1.34 ± 0.40 0.367
Inter-subregional ratios
AP/PP 1.82 ± 0.41 1.81 ± 0.42 0.919
AC/PP 1.78 ± 0.53 1.85 ± 0.58 0.443
VP/PP 1.19 ± 0.19 1.18 ± 0.23 0.877
VS/PP 2.09 ± 0.69 2.12 ± 0.70 0.797
PC/PP 1.09 ± 0.31 1.16 ± 0.40 0.282
Data are means ± SDs. 
VS: ventral striatum, AC: anterior caudate, PC: posterior caudate, AP: anterior 
putamen, PP: posterior putamen, VP: ventral putamen.
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The correlations between subregional DAT activities and the each domain 
score of the NMSS after controlling for follow-up duration are shown in Table 3.
The mood/cognition domain score significantly and negatively correlated to the 
anterior putamen/posterior putamen ISR (r = -0.175, p = 0.032) (Figure 3). In 
contrast, the cardiovascular and sleep/fatigue domain scores positively 
correlated with the anterior caudate/posterior putamen ISR. The other NMSS
domain scores and total NMSS score did not correlate to subregional DAT 
activities.
Table 3. Correlation between 18F-FP-CIT uptakes and the each domain score of 
the NMSS
Cardio-
vascular
Sleep/
Fatigue
Mood/
Cognition
Perceptual/
Hallucina-
tions
Attention/
Memory
Gastro-
intestinal
Urinary
Sexual 
function
Miscella-
neous
Total
Inter-subregional ratios
AP/PP 0.091 0.067 -0.175* -0.011 -0.067 0.042 -0.068 0.060 -0.134 -0.079
AC/PP 0.184* 0.176* -0.117 0.087 0.029 0.030 -0.095 0.034 -0.034 -0.004
VP/PP 0.108 0.016 -0.063 -0.015 -0.061 0.079 -0.124 -0.014 -0.036 -0.053
VS/PP 0.159 0.047 -0.116 0.054 -0.037 0.133 -0.043 0.013 -0.079 -0.020
PC/PP 0.156 0.157 -0.081 0.086 0.041 0.069 -0.089 0.083 0.034 0.034
Significant difference across groups, *p < 0.05.
VS: ventral striatum, AC: anterior caudate, PC: posterior caudate, AP: anterior 
putamen, PP: posterior putamen, VP: ventral putamen.
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Figure 3. A scatterplot showing anterior putamen/posterior putamen 
inter-subregional ratio and the mood/cognition domain score of the NMSS in 
each patient. There is significant negative correlation after adjustment for 
follow-up duration.
17
IV. DISCUSSION
This study demonstrated that high NMSS patients showed different clinical 
characteristics, such as an older onset age, more severe motor symptoms, and 
more severe depression, when compared to low NMSS patients. DAT activities 
in the striatal subregions and ISRs in high NMSS patients were similar to those 
in low NMSS patients. After controlling DAT activity in the posterior putamen 
as well as onset age, gender, motor symptom duration and BDI score in each 
patient, UPDRS-motor scores were still higher in high NMSS patients than low
NMSS patients. This result suggests that low NMSS patients shows either a 
more benign course or a greater reserve compensating for the pathological 
processes when compared to high NMSS patients. Less LED in low NMSS 
patients when compared to that in high NMSS patients after similar follow-up 
duration support this assumption. Although the total NMSS score did not 
correlated to ISRs, the mood/cognition domain score correlated inversely and
significantly with the anterior putamen/posterior putamen ISR, and the 
cardiovascular and sleep/fatigue domain scores correlated positively and 
significantly to the anterior caudate/posterior putamen ISR. The inverse 
relationship between mood/cognition and the anterior putamen/posterior 
putamen ISR suggests that patients with greater DAT defects in the anterior 
putamen relative to those in posterior putamen shows greater deficits in 
mood/cognition function. However, the meaning of the positive relationship 
between cardiovascular, sleep/fatigue and the anterior caudate/posterior 
putamen ISR is uncertain and might be incidental, because it is hard to explain 
how greater DAT defects in the anterior caudate is associated with less 
18
cardiovascular and sleep/fatigue dysfunction.
The mean NMSS score in our patients was relatively lower than that in the 
original study,13 presumably because we enrolled early stage PD patients. The 
association between NMS and PD progression has been well documented in a 
number of studies, in which a number of NMS increases along with PD duration, 
HYS, and UPDRS scores.13,17 In this study, high NMSS patients also showed a 
higher UPDRS-motor score than low NMSS patients, which is compatible to 
the previous studies. Because depression is a main component of the 
mood/cognition domain of the NMSS, and could be an important factor
influencing other NMS such as sleep/fatigue, attention/memory, and so on, it is 
fully expected that high NMSS patients had a higher BDI score, i.e., a greater 
depression, than low NMSS patients. In this study, high NMSS patients were 
older at PD symptom onset than low NMSS patients. Because many of NMSs 
can be associated with aging in healthy people, this result is also predictable 
like as previous study.18
PD symptoms do not develop until 50 - 60% of the dopaminergic neurons in 
the substantia nigra are lost,19 suggesting the presence of a mechanism for 
compensation in the motor system. The ability of the brain to show no 
functional impairment until the damage reaches a critical threshold, which is 
called compensatory ability, may reflect an individual’s neuronal reserve.20
Similarly, in the present study, the low NMSS patients showed less motor 
deficits when compared to the high NMSS patients, despite a similar degree of 
striatal dopamine reduction in the posterior putamen. Therefore, PD patients 
with less NMS represent either a more benign course or a greater reserve 
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compensating for the pathological process when compared to those with greater 
NMS.
The mood/cognition domain of the NMSS contains apathy, anxiety, fear, 
depression, and dysthymia. Depression, anxiety, and apathy belong to the most 
common hypodopaminergic behavioral syndrome in PD patients.21 Previous 
research that used [11C]RTI-32 PET (an in vivo marker of both dopamine and 
noradrenaline transporter binding) detected decreased binding in the locus 
coeruleus and in several regions of the limbic system including the anterior 
cingulate cortex, thalamus, amygdala and ventral striatum in PD patients with 
depression and anxiety. In addition, apathy was inversely correlated with 
[11C]RTI-32 binding in the ventral striatum, not in the caudate or the putamen.22
A previous study performed in PD patients has shown an association between 
depression and altered putamen metabolism.23 Among the studies using DAT
SPECT, one showed that anxiety and depression were associated with reduced
DAT activity in the left anterior putamen,24 while the other demonstrated that 
anxiety severity was related with reduced DAT activity in the right caudate.25
Thus, previous studies suggest a potential connection between affective 
symptoms in PD and striatal DAT reduction, although this assumption is still 
controversial. The present result showing an association between the degree of 
NMS and DAT reduction in the anterior putamen may provide an additional 
evidence to support the above assumption.
Recent studies have demonstrated that excessive daytime sleepiness and RBD
in early PD patients are correlated with decreased striatal DAT binding.26 27
Another study has also shown that fatigue in PD is related to reduced 
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dopaminergic function in the caudate and the insula.28 In this study, the anterior 
caudate/posterior putamen ISR was positively correlated with the sleep/fatigue 
domain score, which is quite opposite to the results shown in the above studies. 
In addition, the anterior caudate/posterior putamen ISR was also positively 
correlated with the cardiovascular domain score. Dopamine has a complex role 
in the sleep-wake cycle, and, in PD, sleep-related problems might be dopamine 
sensitive.29 Also, the sleep/fatigue domain contains diverse symptoms of sleep, 
such as hypersomnia and insomnia, while the cardiovascular domain is only 
composed of two questions. These factors could have effect on distinct result 
from previous studies. Thus, it is hard to explain how greater DAT reduction is 
associated with less NMS, these results appear to be an incidental rather than a 
clinically relevant finding.  
In this study, other NMSS domain scores were not correlated to striatal 
subregional ISRs. Previous studies have shown that reduced DAT uptakes in the 
caudate, ventral striatum, and anterior cingulate cortex are associated with
cognitive impairment in PD,30,31 while another study using 18F-Dopa PET have 
demonstrated no significant correlation between cognitive abilities of 
non-demented PD and striatal dopaminergic depletion.32
Selection of de novo PD patients in this study minimized the influence of any 
PD medication on the assessments of striatal dopamine depletion and motor 
deficits. A programmed measure of striatal dopamine activities could minimize 
the inter- and intra-rater variability. However, a longitudinal follow-up study is 
warranted to assess whether PD patients with less NMS show more benign 
course of PD progression.
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V. CONCLUSION
This study demonstrates that the pattern of striatal dopamine depletion does 
not contribute to the degree of NMS in early PD, although some clinical 
features are different between the patients with greater NMS and those with less 
NMS. Our research also suggests that patients with less NMS may have a more 
benign course of motor symptom progression or a greater reserve compensating 
for the pathological process, compared to those with more NMS. NMS in PD
may be more likely associated with extra-striatal lesions accompanied in PD 
than striatal dopaminergic deficits. Further functional imaging study that handle
pathogenesis underlying NMS in PD should be necessary, and it will be able to 
contribute to develop future therapeutic targets. A prospective and long term 
follow-up study is required to investigate striatal dopaminergic system 
associated with NMS.
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ABSTRACT(IN KOREAN)
파킨슨병 환자에서 선조체의 도파민 감소가 비운동 증상에
기여하는가?
<지도교수 손영호>
연세대학교 대학원 의학과
정 수 진
목적 : 파킨슨병의 비운동 증상은 삶의 질에 영향을 미치는 주요한
요인으로 알려져 있으나, 이에 대한 정확한 병태생리는 정립된 바가
없다. 선조체 도파민의 감소 양상이 파킨슨병의 비운동 증상에
영향을 미치는지 알아보기 위하여, 본 연구는 비운동 증상이 심한
파킨슨병 환자일수록 뒤쪽 조가비핵보다 오히려 다른 부위의
선조체에 도파민 신경세포의 감소율이 심할 것이라고 가정하였다.
방법 : 본원에서 2009년 3월부터 2013년 6월까지 파킨슨병을 처음
진단받았고, 진단 당시에 [18F] N-(3-Fluoropropyl)-2β-carbon 
ethoxy-3β-(4-iodophenyl) nortropane (FP-CIT) 양전자 방출
단층촬영을 시행한 151명의 환자를 대상으로 비운동 증상 평가 척도
(NMSS)를 작성하였다.
결과 : 비운동 증상 평가 척도의 점수가 높은 (중앙값 이상) 환자들이
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점수가 낮은 환자들에 비하여 발병연령이 높았고 (64.9 ± 9.1 vs 
61.5 ± 10.1 years, p = 0.034), 초기의 통합파킨슨병척도운동점수
(UPDRS-motor)가 높았으며 (26.9 ± 11.7 vs 20.9 ± 10.3, p = 
0.003), 레보도파 일용량이 높았고 (636.3 ± 293.0 vs 524.4 ±
196.2, p = 0.007), 벡 우울척도 (BDI) 점수가 높았다 (14.7 ± 8.1 vs 
11.5 ± 7.5, p = 0.013). 발병연령, 성별, 이환기간, 벡 우울척도 점수
및 뒤쪽 조가비핵의 도파민 활성도를 보정한 후의
일반선형모형에서는 비운동 증상 평가 척도의 점수가 높은 환자들의
통합파킨슨병척도운동점수가 의미있게 높았다. 그러나 선조체
6구역과 소구역간의 비 (ISRs)는 두 군간에 차이가 없었다. 비운동
증상 평가 척도의 기분/인지 영역의 점수는 앞쪽 조가비핵/뒤쪽
조가비핵의 도파민 활성도 소구역간의 비와 음의 상관관계를
보였으나 (r = -0.175, p = 0.032), 총 점수 및 다른 영역의 점수와
선조체 소구역의 도파민 활성도 간에는 의미있는 상관관계가 없었다.
결론 : 본 연구는 선조체 도파민의 감소 양상이 초기 파킨슨병의
비운동 증상에 영향을 미치지는 않지만, 비운동 증상이 심한 환자와
경한 환자 사이에 임상 양상의 차이가 난다는 점을 나타낸다. 또한
비운동 증상이 경한 환자들은 운동 증상의 진행이 더디다는 것을
시사한다. 파킨슨병의 비운동 증상은 선조체의 도파민 감소보다는
파킨슨병과 연관된 선조체 외의 병변으로 인하여 초래될 것이다.
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